

**United Kingdom-Runcorn: Pharmaceutical products**  
**OJ S 80/2017 25/04/2017**  
**Contract award notice**  
**Supplies**

**Legal Basis:**

Directive 2014/24/EU

---

**Section I: Contracting authority**

**I.1. Name and addresses**

Official name: Commercial Medicines Unit  
Postal address: 2nd Floor, Rutland House  
Town: Runcorn  
NUTS code: UK United Kingdom  
Postal code: WA7 2ES  
Country: United Kingdom  
E-mail: [michelle.clarke6@nhs.net](mailto:michelle.clarke6@nhs.net)  
**Internet address(es):**  
Main address: <https://cmu.bravosolution.co.uk>

**I.4. Type of the contracting authority**

Ministry or any other national or federal authority, including their regional or local subdivisions

**I.5. Main activity**

Health

---

**Section II: Object**

**II.1. Scope of the procurement**

**II.1.1. Title**

NHS Framework Agreement for branded pharmaceuticals — Midlands and East — Tranche B.

**II.1.2. Main CPV code**

33600000 Pharmaceutical products

**II.1.3. Type of contract**

Supplies

**II.1.4. Short description**

NHS Framework Agreement for Branded Pharmaceuticals for Midlands and East of England  
Tranche B

Offer reference number: CM/PHR/14/5448.

Period of framework agreement: 1.3.2017 to 28.2.2019 plus an option to extend for up to 24 months.

**II.1.6. Information about lots**

This contract is divided into lots: yes

**II.1.7.**

## **Total value of the procurement**

Value excluding VAT: 409 517 948,00 GBP

### **II.2. Description**

#### **II.2.1. Title**

Midlands and East comprising West Midlands, East Midlands and East of England  
Lot No: 1

#### **II.2.2. Additional CPV code(s)**

33600000 Pharmaceutical products

#### **II.2.3. Place of performance**

NUTS code: UKH East of England  
NUTS code: UKF East Midlands (England)  
NUTS code: UKG West Midlands (England)

#### **II.2.4. Description of the procurement**

Products associated with the lots are listed on Document No 06c of the Invitation to Offer. Each individual National Product Code (NPC) pack description in each of the regions (Midlands and East, West Midlands, East Midlands and East of England) is deemed to be a separate product for the application of the award criteria. There is no restriction on the number of products that bidders can offer for, or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector.

#### **II.2.5. Award criteria**

Quality criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over  
Cost criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

#### **II.2.11. Information about options**

Options: no

#### **II.2.13. Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds:  
no

#### **II.2.14. Additional information**

### **II.2. Description**

#### **II.2.1. Title**

West Midlands  
Lot No: 2

#### **II.2.2. Additional CPV code(s)**

33600000 Pharmaceutical products

#### **II.2.3. Place of performance**

NUTS code: UKG West Midlands (England)

#### **II.2.4. Description of the procurement**

Offer. Each individual National Product Code (NPC) pack description in each of the regions (Midlands and East, West Midlands, East Midlands and East of England) is deemed to be a separate product for the application of the award criteria. There is no restriction on the number of products that bidders can offer for, or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector.

#### **II.2.5. Award criteria**

Quality criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

Cost criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

#### **II.2.11. Information about options**

Options: no

#### **II.2.13. Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds:  
no

#### **II.2.14. Additional information**

##### **II.2. Description**

##### **II.2.1. Title**

East Midlands  
Lot No: 3

##### **II.2.2. Additional CPV code(s)**

33600000 Pharmaceutical products

##### **II.2.3. Place of performance**

NUTS code: UKF East Midlands (England)

##### **II.2.4. Description of the procurement**

Offer. Each individual National Product Code (NPC) pack description in each of the regions (Midlands and East, West Midlands, East Midlands and East of England) is deemed to be a separate product for the application of the award criteria. There is no restriction on the number of products that bidders can offer for, or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector contractors and agents working on behalf of the above.

##### **II.2.5. Award criteria**

Quality criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

Cost criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

### **II.2.11. Information about options**

Options: no

### **II.2.13. Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds:  
no

### **II.2.14. Additional information**

#### **II.2. Description**

##### **II.2.1. Title**

East of England  
Lot No: 4

##### **II.2.2. Additional CPV code(s)**

33600000 Pharmaceutical products

##### **II.2.3. Place of performance**

NUTS code: UKH East of England

##### **II.2.4. Description of the procurement**

Offer. Each individual National Product Code (NPC) pack description in each of the regions (Midlands and East, West Midlands, East Midlands and East of England) is deemed to be a separate product for the application of the award criteria. There is no restriction on the number of products that bidders can offer for, or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may als..

##### **II.2.5. Award criteria**

Quality criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

Cost criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

### **II.2.11. Information about options**

Options: no

### **II.2.13. Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds:  
no

### **II.2.14. Additional information**

## **Section IV: Procedure**

---

#### **IV.1. Description**

##### **IV.1.1. Type of procedure**

Open procedure

##### **IV.1.3. Information about a framework agreement or a dynamic purchasing system**

#### **IV.1.8. Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: yes

#### **IV.2. Administrative information**

#### **IV.2.8. Information about termination of dynamic purchasing system**

#### **IV.2.9. Information about termination of call for competition in the form of a prior information notice**

### **Section V: Award of contract**

---

A contract/lot is awarded: yes

#### **V.2. Award of contract**

##### **V.2.1. Date of conclusion of the contract**

13/02/2017

##### **V.2.2. Information about tenders**

Number of tenders received: 30

The contract has been awarded to a group of economic operators: no

##### **V.2.3. Name and address of the contractor**

Official name: For details of the awarded supplier, please see section VI.2)

Town: Runcorn

NUTS code: UK United Kingdom

Country: United Kingdom

The contractor is an SME: no

##### **V.2.4. Information on value of the contract/lot**

Total value of the contract/lot: 409 517 948,00 GBP

##### **V.2.5. Information about subcontracting**

### **Section VI: Complementary information**

---

#### **VI.3. Additional information**

Awarded suppliers -

Astellas Pharma Ltd;

AstraZeneca UK Ltd;

Aventis Pharma Ltd trading as Sanofi;

Basilea Pharmaceuticals Ltd;

Bayer Plc;

Biogen Ltd;

Bristol-Myers Squibb Pharmaceuticals Limited;

Daiichi Sankyo UK Ltd;

Eli Lilly and Company Ltd;

Ferring Pharmaceuticals Limited;

Finox Biotech;

Genzyme Therapeutics Ltd;

Gilead Sciences Ltd;

Ipsen Limited;

Janssen-Cilag Ltd;  
LEO Pharma;  
Merck Pharmaceuticals;  
MSD;  
Napp Pharmaceuticals Ltd;  
Novartis Pharmaceuticals UK Ltd;  
Novo Nordisk Ltd;  
Pfizer Ltd;  
Pharmasure Ltd;  
Roche Products Ltd;  
Takeda UK;  
Teva UK Ltd;  
UCB Pharma Ltd.

**VI.4. Procedures for review**

**VI.4.1. Review body**

Official name: Commercial Medicines Unit  
Town: Runcorn  
Country: United Kingdom

**VI.5. Date of dispatch of this notice**

21/04/2017